Analyst reports.
This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.
Analyst Reports 2023
Analyst Reports 2023
September 10th 2023
CLSA - FY24 a pivotal year with key readouts ahead and cash runway to CY26. Mtn Buy, A$0.95 Tgt (Analyst: Andrew Paine)
August 31st 2023
Jefferies - FY23: I Say A Little Prayer; Mtn Buy and A$1 tgt (Analyst: Dr David Stanton)
August 28th 2023
Baird - Efti Continues to Look More Promising than Anti-TIGIT; $7 tgt (Analysts: Joel L. Beatty and Benjamin E. Paluch)
August 2nd 2023
Baird - Unique LAG-3 Agent with Fast Track Designation; Initiate OP, $7 tgt
July 3rd 2023
Bell Potter - Cash Secured. Readouts 2H CY2023. (Analyst: Thomas Wakim)
May 29th 2023
Petra Capital - 2L HNSCC detailed results: Wait for ASCO; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)
May 25th 2023
Petra Capital - Triple combo data in NSCLC shows promise; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)
May 24th 2023
Bell Potter - Efti's Efficacy - Strong Rationale for Prioritising NSCLC (Analyst: Thomas Wakim)
May 18th 2023
Petra Capital - First OS look in NSCLC impresses; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)
May 17th 2023
Maxim Group: Efti+Keytruda Leads to Positive Survival Data in 1L Lung Cancer; Raise tgt to $10, mtn Buy (Jason McCarthy, PhD)
May 17th 2023
CLSA - Efti & Keytruda’s excellent adventure; OS data shows meaningful benefit in NSCLC, without need for chemo (Analyst: Andrew Paine)
April 28th 2023
Petra Capital - Immutep Ltd (IMM) - 3QFY23 – Clinical Progress on all fronts; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)
April 19th 2023
Maxim Group - New Efti Trial Announced in Sarcoma; Moving into Neoadjuvant Setting; Buy, $8 tgt (Jason McCarthy, PhD)
April 5th 2023
Petra Capital - Immutep Ltd (IMM) - Efti activity in PD-1 refractory patients re-confirmed; Reit Buy, A$1.28 Tgt (Analyst: Tanushree Jain)
April 3rd 2023
Ladenburg Thalmann - Final 2L Lung Data Looks Fine; the Focus Is on 1L NSCLC; Reit Buy, $8.30 Tgt (Dr Ahu Demir)
March 14th 2023
Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing & OS Primary in Breast Cancer; Buy, $8 tgt (Jason McCarthy, PhD)
March 8th 2023
CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)
February 28th 2023
Petra Capital - Immutep Limited (IMM) - Accelerating clinical and manufacturing work (Analyst: Tanushree Jain)
February 10th 2023
Petra Capital - Immutep - The stage is set for an explosive 2023; Reit Buy & lift TP by 8% to A$1.30 (Analyst: Tanushree Jain)
January 31st 2023